KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (2016 - 2025)

Pacira BioSciences (PCRX) has 14 years of Shares Outstanding data on record, last reported at $46.4 million in Q3 2023.

  • For Q3 2023, Shares Outstanding rose 1.23% year-over-year to $46.4 million; the TTM value through Sep 2023 reached $46.4 million, up 1.23%, while the annual FY2022 figure was $45.9 million, 2.67% up from the prior year.
  • Shares Outstanding reached $46.4 million in Q3 2023 per PCRX's latest filing, roughly flat from $46.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $46.4 million in Q3 2023 and bottomed at $41.3 million in Q1 2019.
  • Average Shares Outstanding over 5 years is $44.1 million, with a median of $44.4 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: rose 4.37% in 2021, then grew 1.23% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $41.9 million in 2019, then increased by 4.13% to $43.6 million in 2020, then increased by 2.51% to $44.7 million in 2021, then grew by 2.67% to $45.9 million in 2022, then increased by 1.09% to $46.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $46.4 million in Q3 2023, $46.4 million in Q2 2023, and $46.0 million in Q1 2023.